Main Article Content

Abstract

The present study has been undertaken to evaluate the possible role of Mimusops elengi Linn. flowers in experimental Alzheimer's disease (AD) in rats. Experimental AD in rats was produced by intra cerebro ventricular (i.c.v) administration of colchicine (Col). Various behavioural tests and biochemical analysis were performed to explore the possible role of the Mimusops elengi Linn. flower extract (ME)(100mg/kg & 200mg/kg doses) in AD. ME exhibited anxiolytic activity in Elevated plus maze test. In Morris' water maze test and Brightness discrimination test, ME pretreatments improved reference memory, working memory and spatial learning.ME significantly reduced the acetylcholinestarase. It  reduced the Col induction increased lipid peroxidase activity, which was significantly reversed by ME (as seen from the reductions in the malondialdehyde level) and stabilized the rise in superoxide dismutase activity.ME might be effective in clinical AD by virtue of its cognition enhancement, anti-oxidant and antianxiety properties, which are the primary needs to be addressed in AD.

Keywords

Alzheimer′s disease Anxiolytic activity Colchicine Rats Mimusops elengi Linn

Article Details

How to Cite
Bhukya Ramesh, & Santhosh Pawar V. (2021). Evaluation of alzhiemer’s disease of mimusops elengi linn. in the experimental model of rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(4), 446-454. https://doi.org/10.61096/ijrpp.v4.iss4.2015.446-454

References

  1. [1]. Chittaranjan Andrade, J.Suresh Chaadra. Anti-amnesic properties of Brahmi and Mandookaparni in a rat model. Indian Journal of Pschiatry. 2006; 48: 232-237.
  2. [2]. Sharma A,Parikh V,Singh M. Pharmacological basis of drug therapy of Alzhiemer’s disease. Indian Journal of Experimental Biology; 35(199): 1146-115.
  3. [3]. Bennett, Plum. Cecil Text book of Medicine. 20th ed: Prism India Pvt Ltd, 1996; p. 2047.
  4. [4]. "Alzheimer's diagnosis of AD". Alzheimer's Research Trust. http://www.alzheimers- research.org.uk/info/diagnosis. Retrieved 2008-02-29.
  5. [5]. Landes AM, Sperry SD, Strauss ME, Geldmacher DS (Dec 2001). "Apathy in Alzheimer's disease". Journal of American Geriatics; 49 (12): 1700–7.
  6. [6]. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (May 2001). "Sundowningandcircadian rhythms in Alzheimer's disease". American Journal of Psychiatry; 158 (5): 704–11.
  7. [7]. Holmes C, Boche D, Wilkinson D, et al. (July 2008). "Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial"; Lancet 372 (9634): 216–23.
  8. [8]. Shen ZX (2004). "Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease". Medical Hypotheses; 63 (2): 308–21.
  9. [9]. M.Raghavendra, Rituparna Maiti,Shafalika Kumar,S.B.Acharya. Role of Ocimum sanctum in the experimental model of Alzhiemer’s disease in rats. Journal of Green pharmacy 2009; 6-15.
  10. [10]. Moan R (July 20, 2009). "MRI software accurately IDs preclinical Alzheimer’s disease”.
  11. [11]. Vaidyaratnam P.S.Varier. Indian Medicinal Plants (1)-A Compendium of 500 species. Orient Longmann Pvt Ltd, 1988; p.361- 365.
  12. [12]. The Wealth of India (L-M), Vol: 6: Publications & Information Directorate, CSIR, 1995; p.205.
  13. [13]. Chopra R.N, Nayar S.L, Chopra I.C. Glossary of Indian Medicinal Plants. National Institute of Science Communications, 1956; p.167.
  14. [14]. The useful plants of India. Publications & Information Directorate, CSIR,1992 ;p. 375.
  15. [15]. N. Raaman. Phytochemical Techniques. New India Publishing Agency, 2006; p.10, 19-24.
  16. [16]. Drug Discovery and Evaluation-Pharmacological assays, H.Gerhard Vogel. 2nd Ed: p.428-439.
  17. [17]. Pawel Boguszewski, Jolanta Zagrodska. Emotional changes related to age in rats-a behavioural analysis. Behavioural brain research 2002;133:323-332.
  18. [18]. Nirmal Sethi, Sanjay Dube,H.K.Singh. Effect of Chronic Administration of lithium on Memory functions in Rats. Indian Journal of Psychiatry 1983;25(2):102-106.